



EXPERIMENTICA[®]
Scientific Excellence in Ocular ModelsSM

FOR IMMEDIATE RELEASE

**EXPERIMENTICA LTD. RECEIVES FRENCH CRÉDIT D'IMPÔT RECHERCHE (CIR)
ACCREDITATION FOR 2020-2022**

Unlocks CIR Research Tax Credit Incentive for French Customers and Prospects

Kuopio, FINLAND, and Marseille, FRANCE – September 22, 2020

Experimentica Ltd., a leader in preclinical ophthalmic drug discovery services, announces that they received an accreditation to the *Crédit d'Impôt Recherche* (CIR) tax credit incentive from the French Ministry of Higher Education, Research and Innovation, covering cross-border R&D projects with innovative French companies from 2020 to 2022.

France's CIR research tax credit incentive covers up to 30% of R&D expenses incurred by French pharma and biotech companies working with CIR-accredited contract research organizations (CROs).

CIR accreditation will translate into a significant financial benefit to Experimentica's customers in France and will allow us to bring our expertise to a broader number of companies developing innovative drugs in Ophthalmology.

Giedrius Kalesnykas, Ph.D., President and CEO of Experimentica Ltd., commented, "We are delighted to receive this accreditation from the French Ministry. This is an additional recognition of our R&D activities in preclinical ophthalmic model development. We look forward to turning our innovative R&D work as a product offering to our sponsors in France."

"Experimentica's CIR accreditation is excellent news to French pharma and biotech companies developing preclinical assets in Ophthalmology at a time when executives are seeking new research partners with world-class expertise while facing financial constraints and challenging fundraising trends", **Guillaume Demarne, Pharm.D., Director of Business Development of Experimentica Ltd.**, commented.



EXPERIMENTICA[®]
Scientific Excellence in Ocular ModelsSM

About Experimentica Ltd.:

Experimentica Ltd. is a global contract research organization (CRO) that specializes in preclinical models of ophthalmic disease. Our world-class scientists and technicians apply a comprehensive set of skills and industry experience to model ocular diseases using multiple experimental platforms, from cell culture-based systems to complex surgical techniques and in vivo models. With R&D laboratory sites in Kuopio, Finland, Vilnius, Lithuania, and Grand Rapids, Michigan, USA, global representation and an industry-leading portfolio, Experimentica Ltd. delivers the highest quality science to assist clients around the globe in advancing their ophthalmic drug discovery and drug development portfolio.

Learn more about Experimentica at www.experimentica.com

Contact for media enquiries:

Guillaume Demarne, Pharm.D., Director of Business Development

Email: gd@experimentica.com

Phone: +33 (0) 7 83 55 69 52